Two Novartis Drugs Win Backing in Final U.K. Leukemia Guidance

Novartis AG (NOVN)’s Tasigna and Glivec drugs won the backing of the U.K.’s health-cost agency for use against a rare blood cancer in final treatment guidelines.

The National Institute for Health and Clinical Excellence rejected a competing product, Bristol-Myers Squibb Co. (BMY)’s Sprycel, for use in patients with chronic myeloid leukemia, the agency said in a statement today. The agency advises the National Health Service on which medicines represent value for money.

Novartis offered a price cut that allowed a recommendation for Tasigna, and the Basel, Switzerland-based company asked that the discount be kept confidential, the agency said.

To contact the reporter on this story: Kristen Hallam in London at khallam@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.